In line with this result, common insertion site (CIS) analysis by the Grubbs test for outliers36 showed that MECOM was a CIS only in the IS dataset from the US cohort of ADA patients, while LMO2 appeared as a CIS in all the 3 different datasets (Fig. 5d), and resulted most frequently targeted in P21 compared to the other Sr-TIGET cohort of patients (Fig. 5c). Here, MECOM is linked to in situ carcinoma.